Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 7.5 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - lenalidomide - hard capsule - lenalidomide 20 mg - lenalidomide - multiple myeloma (mm)lenalidomide s.k. is indicated for the treatment of multiple myeloma. myelodysplastic syndromes lenalidomide s.k. is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. lenalidomide s.k. 7.5 mg is not indicated for treatment in mds. mantle cell lymphoma lenalidomide s.k. is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl). follicular lymphomalenalidomide s.k. in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - decitabine - powder for concentrate for solution for infusion - decitabine 50 mg/vial - decitabine - decitabine s.k. is indicated for treatment of patients with myelodysplastic syndromes (mds) including previously treated and untreated, de novo and secondary mds of all french-american-british subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2 and high-risk international prognostic scoring system groups. decitabine s.k. is indicated for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia (aml), according to the world health organisation (who) classification, who are not candidates for standard induction chemotherapy

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - esomeprazole as sodium - hard capsule - esomeprazole as sodium 20 mg - esomeprazole - esoprim s.k. 20 mg indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease. in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori and- healing of helicobacter pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers -patients requiring continued nsaid therapy healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk. - prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. esoprim s.k 20 mg is indicated in adolescents from the age of 12 years for: gastro-esophageal reflux disease (gerd) - treatment of erosive reflux esophagitis -long-term management of patients with healed esophagitis to prevent relapse-symptomatic treatment of gastro-esophageal reflux diseasein combination with antibiotics in treatment of duodenal ulcer caused by helicobacter pylori.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - esomeprazole as sodium - hard capsule - esomeprazole as sodium 40 mg - esomeprazole - esoprim s.k. 40 mg is indicated in adults for:gastroesophageal reflux disease (gerd)- treatment of erosive reflux esophagitis - long-term management of patients with healed esophagitis to prevent relapse - symptomatic treatment of gastroesophageal reflux disease in combination with appropriate antibacterial therapeutic regimens for the eradication of helicobacter pylori and- healing of helicobacter pylori associated duodenal ulcer and prevention of relapse of peptic ulcers in patients with helicobacter pylori associated ulcers -patients requiring continued nsaid therapy healing of gastric ulcers associated with nsaid therapy. - prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk. - prolonged treatment after i.v. induced prevention of rebleeding of peptic ulcers. esoprim s.k 40 mg is indicated in adolescents from the age of 12 years for: gastro-esophageal reflux disease (gerd) - treatment of erosive reflux esophagitis

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - treprostinil - solution for injection / infusion - treprostinil 10 mg / 1 ml - treprostinil - treprostinil s.k. is indicated for the treatment of:* primary pulmonary arterial hypertension.* pulmonary arterial hypertension associated with connective tissue disorders. * pulmonary hypertension associated with congenital systemic to pulmonary shunts.

Իսրայել - անգլերեն - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - treprostinil - solution for injection / infusion - treprostinil 2.5 mg / 1 ml - treprostinil - treprostinil s.k. is indicated for the treatment of:* primary pulmonary arterial hypertension.* pulmonary arterial hypertension associated with connective tissue disorders. * pulmonary hypertension associated with congenital systemic to pulmonary shunts.